Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
| ▸ | BCKDK | O14874 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29937094 | 0.83 | MAPT (0.40) | CYP1A2CYP2A6KDM4EMAPTALDH1A1 | |
| SCHEMBL1992185 | 0.83 | MAPT (0.40) | CYP1A2CYP2A6KDM4EMAPTALDH1A1 | |
| SCHEMBL15647791 | 0.80 | KDM4E (0.36) | CYP1A2CYP2A6KDM4EMAPTALDH1A1 | |
| SCHEMBL27243965 | 0.78 | CYP2A6 (0.39) | GRM4CYP2A6ALDH1A1KMT2AACHE | |
| SCHEMBL15019506 | 0.76 | TRPA1 (0.40) | CYP1A2ALDH1A1 | |
| SCHEMBL15647832 | 0.76 | MAPT (0.38) | CYP1A2KDM4EMAPTALDH1A1KMT2A | |
| SCHEMBL18769974 | 0.75 | CYP1A2 (0.42) | GRM4CYP1A2CYP2A6KDM4EMAPT | |
| SCHEMBL31729204 | 0.75 | HSD17B10 (0.38) | GRM4CYP1A2KDM4EMAPTALDH1A1 | |
| SCHEMBL30160405 | 0.75 | CYP1A2 (0.42) | GRM4CYP1A2CYP2A6KDM4EMAPT | |
| SCHEMBL19681404 | 0.75 | GRM4 (0.40) | GRM4KDM4EMAPTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368616-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2025-12-04 | — | — | US | disclosed |
| US-20250206718-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| EP-4495110-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2025-01-22 | — | — | EP | disclosed |
| CN-118871433-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-4393916-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-4393916-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| CN-117813299-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023174406-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2023-09-21 | — | — | WO | disclosed |
| WO-2023025320-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2023-03-02 | — | — | WO | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| EP-2125746-B1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES | SANOFI SA (FR) | 2012-04-18 | — | — | EP | disclosed |
| US-20110245248-A1 | ISOQUINOLINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | US | disclosed |
| US-20110245248-A1 | ISOQUINOLINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | US | disclosed |
| US-20100081671-A1 | Cycloalkylamine substituted isoquinoline derivatives | SANOFI-AVENTIS (FR) | 2010-04-01 | — | — | US | disclosed |
| US-20100081671-A1 | Cycloalkylamine substituted isoquinoline derivatives | SANOFI-AVENTIS (FR) | 2010-04-01 | — | — | US | disclosed |
| EP-1899322-B1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE | SANOFI AVENTIS (FR) | 2009-09-02 | — | — | EP | disclosed |
| US-20090088429-A1 | Isoquinoline Derivatives | SANOFI-AVENTIS (FR) | 2009-04-02 | — | — | US | disclosed |
| US-20090088429-A1 | Isoquinoline Derivatives | SANOFI-AVENTIS (FR) | 2009-04-02 | — | — | US | disclosed |
| WO-2008077554-A1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| WO-2007000240-A1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE | SANOFI-AVENTIS (DE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081671-A1 | Cycloalkylamine substituted isoquinoline derivatives | MYLK2, MYLK, MYLK3 | GRM4 3030/4885CYP1A2 3771/4885CYP2A6 4002/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | GRM4 1676/4885CYP1A2 445/4885CYP2A6 672/4885 |
| US-20110245248-A1 | ISOQUINOLINE DERIVATIVES | MYLK2, MYLK, RHOT2 | GRM4 3181/4885CYP1A2 2945/4885CYP2A6 3570/4885 |
| US-20250206718-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, EGFR, WEE2 | GRM4 4418/4885CYP1A2 765/4885CYP2A6 719/4885 |
| US-20250368616-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, EGFR | GRM4 4301/4885CYP1A2 1752/4885CYP2A6 1243/4885 |
| US-20090088429-A1 | Isoquinoline Derivatives | MYLK2, MYLK, RHOT2 | GRM4 3181/4885CYP1A2 2945/4885CYP2A6 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.